Key result
Mesenchymal stem cells and derived exosomes show promise for HACEK endocarditis via immunomodulation and antimicrobial peptides.
Why the study?
Mesenchymal stem cells and their exosomes present a promising avenue for treating infectious diseases, warranting an investigation into their therapeutic potential against HACEK-associated infective endocarditis.
Mesenchymal stem cells and their secreted antimicrobial peptides offer a promising preclinical framework for treating HACEK endocarditis, particularly given the challenges of antibiotic resistance.
Answers are grounded in this paper and cite their sources.
Premature for clinical use in HACEK endocarditis; hypothesis-generating and requires prospective trials to validate MSC-exosome therapy.
Extensive research has investigated the therapeutic potential of mesenchymal stem cells (MSCs) in treating infectious diseases and mitigating tissue damage caused by these diseases. MSCs, along with their exosomes, present a promising avenue for combating infectious diseases, particularly HACEK endocarditis (HE). MSCs possess immunomodulatory properties and aid in tissue repair, while exosomes carry bioactive molecules. Antimicrobial peptides (AMPs) released by MSCs demonstrate efficacy against a broad spectrum of microorganisms, including bacteria, fungi, yeasts, and viruses. Key AMPs produced by MSCs include hepcidin, cathelicidin LL-37, and β-defensin-2. Furthermore, these AMPs have been found to interact with MSCs, influencing their proliferation, migration, and regeneration, indicating a broader biological impact than previously recognized. Preclinical studies have highlighted the potential of these AMPs to reduce inflammation, enhance cardiac function, and augment the efficacy of antibiotics against bacterial pathogens. This narrative review investigates the antimicrobial efficacy of MSCs, with specific emphasis on their therapeutic application against HACEK-associated infective endocarditis.
No takes yet. Share an insight, caveat, or question.
Kodori et al. (2026) conducted a review in HACEK endocarditis. Mesenchymal stem cells (MSCs) and MSC-derived exosomes was evaluated. Mesenchymal stem cells and their derived exosomes present a promising therapeutic approach for HACEK endocarditis through immunomodulatory properties and the release of antimicrobial peptides.
Synapse has enriched 10 related papers. Consider them for comparative context: